Jemperli Coupon & Prices

Your monthly Jemperli cost savings if eligible

If you are eligible for the Jemperli patient assistance program you can receive your medication for free. Our monthly service fee of $49 per medication covers the cost of our services in applying for the program and requesting your ongoing refills on your behalf. If you obtain your Jemperli through NiceRx, you will only pay $49 a month regardless of the retail price of your medication.

Am I eligible for the Jemperli patient assistance program?

You could receive your Jemperli without paying the full retail price if you meet the eligibility criteria for assistance. The eligibility requirements are set by the pharmaceutical companies that are providing assistance programs. At NiceRx, we review each application individually, although the main factors considered by most programs are:

• I am a permanent, legal resident of the United States or Puerto Rico
• I am uninsured or my insurance doesn’t cover my medication
• I meet certain income eligibility requirements

How do I apply for Jemperli patient assistance?

We do everything that we can to take the hassle and stress out of applying for patient assistance programs. Simply start by filling in our enrollment application. We will ask for details about your healthcare provider, your insurance, and your household income. This information is required by the pharmaceutical companies you are applying to for assistance. We may also be able to help you access patient assistance for other medications that you have been prescribed, so be sure to tell us about any medications you are taking as well as Jemperli.

NiceRx will review the information you have provided, and if we determine that you may be eligible for assistance, we will seek to enroll you in the Jemperli patient assistance program. We will handle the enrollment process for you by working with your healthcare provider and preparing all the required paperwork for your doctor to sign. We will also request your Jemperli medication refills on your behalf for up to 1 year once you are enrolled in the program.

Is NiceRx a Jemperli coupons provider?

At NiceRx, we help eligible individuals access the Jemperli patient assistance program. This means that we are not a Jemperli coupon, a Jemperli discount card, or a Jemperli copay card provider. We do not offer any medication trial offers or free Jemperli samples.

Can NiceRx help me get Jemperli if I have insurance?

We may be able to help you if you have insurance, including if your insurance company will not pay for your Jemperli medication, or you have a high copay or coinsurance responsibility. We may even be able to assist if you do not have insurance. Please fill in our enrollment application to find out more.

How much does Jemperli cost without insurance?

Jemperli costs without insurance will vary depending on how much you buy and the retailer you buy it from. As a guide, Jemperli intravenous solution (500 mg/10 mL) will typically cost around $10,800 for 10 milliliters. If you obtain your medication through NiceRx, you will pay a flat monthly rate of $49 per medication regardless of its retail price.

How much does Jemperli cost with insurance?

The copay of Jemperli will vary in line with the specific terms of your healthcare plan. For further details about what you may need to pay, your insurance provider or pharmacist will be able to calculate the copay costs with your current insurance.

What is Jemperli?

Jemperli is an FDA (U.S. Food and Drug Administration) approved medication manufactured by GlaxoSmithKline (GSK).

Jemperli is a programmed death receptor-1 (PD-1)–blocking antibody indicated for:

• The treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen.
• Advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options

These indications are approved under accelerated approval based on tumor complete response rate and durability of response.

The new indications follow an FDA review and are based on the results from the dMMR endometrial cancer cohort A1 and the dMMR solid-tumor (non-endometrial cancer) cohort F of the ongoing GARNET trial. The GARNET trial is a multicentre, non-randomized, multiple parallel-cohort, open-label study. The GARNET study represents the largest dataset of anti-PD-1 monotherapy treatment of women with endometrial cancer.

What doses of Jemperli are available?

Jemperli is available in injection form, in the following doses: 500 mg/10 mL (50 mg/mL) solution in a single-dose vial.

Dose 1 to 4 – 500 mg every 3 weeks. Subsequent dosing beginning 3 weeks after Dose 4. Dose 5 onwards – 1,000 mg every 6 weeks. Administer as an intravenous infusion over 30 minutes. Treat patients until disease progression or unacceptable toxicity.

Please see the full prescribing information and always speak with a healthcare professional about any changes to your dose so they can monitor and evaluate your condition.

Jemperli active ingredients

Jemperli contains the active ingredient dostarlimab-gxly, a programmed death receptor-1 inhibitor IgG4 humanized monoclonal antibody. It binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.

Jemperli side effects

The most common side effects of Jemperli in clinical trials include:

• Fatigue, asthenia
• Anemia
• Diarrhea, constipation
• Nausea
• Laboratory abnormalities – decreased lymphocytes, decreased sodium, increased alkaline phosphatase, and decreased albumin, increased transaminases
• Acute kidney injury
• Adrenal Insufficiency

In rare instances, Jemperli can cause more serious adverse reactions. These can include:

• Immune-mediated adverse reactions – pneumonitis, colitis, hepatitis, endocrinopathies, nephritis with renal dysfunction, immune-mediated dermatologic adverse reactions, and solid organ transplant rejection. Evaluate clinical chemistries, including liver enzymes, creatinine, and thyroid function periodically during treatment. Withhold or permanently discontinue treatment and administer corticosteroids based on the severity of the reaction
• Infusion-related reactions
• Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after being treated with a PD-1/PDL1–blocking antibody
• Embryo-fetal toxicity

Your doctor will assess the benefits of using Jemperli against your risk of side effects. Patients are encouraged to report negative side effects or adverse reactions of Jemperli to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Jemperli drug interactions

There is currently no data for Jemperli interactions with other medications. However, other drugs may affect dostarlimab-gxly, including prescription drugs and over-the-counter medicines, vitamins, and herbal products.

Jemperli contraindications

You should not use Jemperli if you:

• Are allergic to the active ingredient dostarlimab-gxly
• Are allergic to any of the other ingredients in Jemperli
• Are pregnant or are planning to become pregnant – Use effective contraception during treatment and for 4 months after their last dose
• Are breastfeeding or are planning to breastfeed – do not breastfeed during treatment and for 4 months after the last dose

Talk to your doctor before using Jemperli if you:

• Are taking any of the medications that could interact with Jemperli

Jemperli generic

Jemperli is the trademark brand name for dostarlimab-gxly manufactured by GlaxoSmithKline. A generic version of dostarlimab-gxly is not available. Generic drugs are generally cheaper than brand-name drugs, but you can still find Jemperli savings through NiceRx.

Related medications

• Imfinzi
• Keytruda

Jemperli research & news

Oct 14, 2022

Drugs

Jemperli side effects and how to avoid them

Jemperli is an FDA-approved brand name medication manufactured by GlaxoSmithKline (GSK). It is classed as a cancer ...